longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Braveheart Bio

BRVE

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -13.95, above the reasonable range, cheaper than 7.32% of the time in the past 1 years, and the industry ranks 196/256, the industry Median -1.33.

-13.95xP/E
$21.41Stock price
$-1.53Earnings per share
-13.95xP/E
Stock price$21.41Earnings per share$-1.53

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-21.01x
Typical range
-22.11x–-16.31x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-54.04x149.86%$56.42B
BAYRYUSBayer
-24.79x--$50.03B
BAYZFUSBayer Aktiengesellschaft
-24.36x--$49.15B
VTRSUSViatris
-48.83x107.75%$20.05B
ELANUSElanco Animal Health
-54.66x129.36%$10.88B
AXSMUSAxsome Therap
-49.76x26.61%$9.54B
VREOFUSVIREO GROWTH INC
-139.41x--$9.36B
CURLFUSCuraleaf Holdings, Inc.
-151.29x--$7.87B
BLTEUSBelite Bio
-64.12x29.87%$6.56B
DFTXUSDefinium Therapeutics
-14.28x53.61%$5.05B
MANEUSVeraDermics
-46.96x97.44%$4.90B
EWTXUSEdgewise Therapeutics
-22.29x137.29%$4.40B
AMLXUSAmylyx Pharmaceuticals
-23.17x1.76%$3.52B
TARSUSTarsus Pharmaceuticals
-71.25x205.82%$3.31B
ELVNUSEnliven Therapeutics
-31.96x5.96%$3.39B
RGCUSRegencell Bioscience
-444.96x--$3.14B
MBXUSMBX Biosciences
-26.11x30.54%$2.72B
SUPNUSSupernus Pharma
-22.31x70.59%$2.45B
GPCRUSStructure Therapeutics
-9.62x100.75%$2.07B
PHVSUSPharvaris BV
-10.97x9.52%$2.18B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.